Abstract
Background
Point-of-care testing (POCT) using rapid diagnostic tests for infectious disease can potentially guide appropriate use of antimicrobials, reduce antimicrobial resistance, and economise use of healthcare resources. POCT implementation in private retail settings such as pharmacies and drug shops could lessen the burden on public healthcare. We performed a narrative review on studies of POCTs in low- and middle-income countries (LMICs), and explored uptake, impact on treatment, and feasibility of implementation.
Methods
We searched MEDLINE/PubMed for interventional studies on the implementation of POCT for infectious diseases performed by personnel in private retail settings. Data were extracted and analysed by two independent reviewers.
Results
Of the 848 studies retrieved, 23 were included in the review. Studies were on malaria (19/23), malaria and pneumonia (3/23) or respiratory tract infection (1/23). Nine randomised controlled studies, four controlled, non-randomised studies, five uncontrolled interventions, one interventional pre-post study, one cross-over interventional study and three retrospective analyses of RCTs were included. Study quality was poor. Overall, studies showed that POCT can be implemented successfully, leading to improvements in appropriate treatment as measured by outcomes like adherence to treatment guidelines. Despite some concerns by health workers, customers and shop providers were welcoming of POCT implementation in private retail settings. Main themes that arose from the review included the need for well-structured training with post-training certification covering guidelines for test-negative patients, integrated waste management, community sensitization and demand generation activities, financial remuneration and pricing schemes for providers, and formal linkage to healthcare and support.
Conclusion
Our review found evidence that POCT can be implemented successfully in private retail settings in LMICs, but comprehensive protocols are needed. High-quality randomised studies are needed to understand POCTs for infectious diseases other than malaria.
Supplementary Information
The online version contains supplementary material available at 10.1186/s12879-023-08480-w.
Keywords: Rapid diagnostic tests, Drug resistance, Communicable diseases, Pharmacies, Feasibility studies
Background
Antimicrobial stewardship
Antimicrobial resistance (AMR) is a critical issue requiring effective antimicrobial stewardship (AMS) [1]. AMS can prevent antibiotic overuse, misuse, and abuse [1] and reduce drug resistance [2], costs, and hospital stays [3, 4]. This is particularly important for low- and middle-income countries (LMICs), who suffer a greater AMR [4] and infectious disease burden [5]. Well-developed stewardship measures applicable to LMICs are thus a research priority.
Point-of-care testing
Diagnostic tests to support appropriate treatment and prescribing are a key component of AMS programmes. However, lower-level healthcare settings in LMICs have limited laboratory and diagnostic capacity. Point-of-care testing (POCT), in which patient specimens are analysed outside of a clinical laboratory, at the site of patient care, by staff who have not been formally trained in laboratories, offers a means of reaching more patients with diagnostic services [6]. POCT represents a promising avenue for enhancing antimicrobial stewardship. For example, C-reactive protein (CRP) testing provides real-time assessment of likelihood of bacterial infection, reducing antibiotic prescribing in primary care [7–10]. In a review, 44% of patients who received CRP tests were prescribed antibiotics at initial consultations for upper respiratory tract infections (RTIs), compared to 63% of those untested [11]. More specific POCTs for particular infectious diseases like malaria can also guide appropriate antimicrobial therapy, thereby contributing to reduced disease burden and resistance, and enabling rapid diagnosis for a disease that previously only relied on clinical diagnosis. A malaria POCT test-and-treat strategy in Zambia reduced paediatric prevalence of malaria by 17% [12]. Moreover, POCTs can help reduce unnecessary use of drugs, staff, and equipment [13], lowering costs. For example, Helicobacter pylori screening reduces the number of patients referred for endoscopy [14].
Implementation in private settings
POCT in private retail settings such as pharmacies and drug shops is particularly promising for LMICs [15], where trained workforce and infrastructure are lacking [16], as they are independent of expensive, centralised laboratories [17]. POCTs are easy to perform, interpret, and transport [18]. Although rapid diagnostics are available in large public hospitals, with median availability of malarial diagnostics reaching 91.6% in 10 LMICs [19], these services are often overloaded [20]. In contrast, primary care tends to lack diagnostics, with only 19.1% median availability [19]. Adding additional diagnostic services in hospitals and primary care would burden the national budget. Hence, POCTs in private settings could make diagnostic services more accessible.
Moreover, pharmacies are an ideal checkpoint for antimicrobial use, as regulations around dispensing antimicrobials are poorly enforced in LMICs, with frequent over-the-counter non-prescribed antimicrobial sales [21]. By detecting or ruling out infection, POCTs can help providers recommend appropriate treatment [22–27]. Their use in pharmacies and drug shops can reduce unnecessary treatment and improve care-seeking behaviours [25–28], while still providing revenue from test sales.
Aim
In this study, we reviewed evidence for implementation of POCTs for infectious diseases in private retail settings in LMICs, to inform future studies and policy design.
Methods
Search strategy
This review was structured with reference to the Scale for the Assessment of Narrative Review Articles (SANRA) [29] and Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) [30]. We searched PubMed/Medline on 26/06/2023, using MeSH headings and synonyms for ‘infectious disease’, ‘rapid diagnostic testing’, and ‘pharmacy’ (full search terms Additional file 1). A manual search of references from other studies was also conducted to include relevant studies. No limit on date of publication was imposed on studies for inclusion.
Inclusion criteria were developed referencing population-intervention-comparison-outcomes (PICO):
Participants: pharmacies and private retailers in LMICs
Interventions: implementation of staff-performed POCT
Comparisons: N/A
Outcomes: feasibility and impact of implementation
Non-private or non-interventional studies (reporting only test accuracy, hypothetical or modelling studies, lacking actual implementation); or not on infectious diseases, were excluded.
Two independent investigators selected papers for full-text screening using Covidence, resolving conflicts by discussion. Investigators designed an abstract screening tool [31] (Additional file 2) and randomly selected 20 papers for standardisation of screening.
Outcomes
A data extraction table was created using Google Sheets 2023. Two authors independently performed extraction of study characteristics, methods, and outcomes:
Uptake: proportion of treatment-seeking patients receiving POCT out of total population studied
Positivity: proportion of patients receiving a POCT who tested positive
Treatment provision: proportions of treatment-seeking patients and of patients not tested receiving intended treatment(s)
Adherence to POCT results: proportions of POCT-negative patients not receiving intended treatment(s) and of POCT-positive patients receiving intended treatment(s)
Referrals: proportion of patients referred elsewhere
Test accuracy: sensitivity, specificity, or positive predictive value of test (if available)
Safety and accuracy of performance of test: proportion of providers safely and correctly performing, interpreting and disposing of POCT (if available)
Recommended/median POCT retail price (if available)
Opinions of providers/customers on POCT
Proportions were expressed as percentages. Individual outcomes were chosen or calculated from cluster data. Additional characteristics extracted were training length/content, supervision, demand-generation activities, referral, and guidelines for those who tested positive or negative on the POCT.
Quality assessment
Article quality was checked against seven of ten relevant features published by the Consensus Working Group of the Joint Programming Initiative on Antimicrobial Resistance: randomized design; use of controls; multi-centre study design; sustainability of intervention (> 12 months); sample size calculation (where relevant); prospective design; and correction for confounding variables [32]. Funding was evaluated for conflicts of interest.
Results
Study selection
From our search strategy, 848 titles were identified, of which 63 studies were screened in full (Fig. 1). 21 studies were excluded based on pre-defined inclusion/exclusion criteria. 19 studies in high-income countries were excluded after review to focus on LMICs. 23 studies were included, including one study detailing the policy implications from another study included in this review [33, 34].
Fig. 1.
PRISMA flow diagram for studies analysed in this narrative review
Study design and characteristics
Table 1 describes characteristics of the included studies. 19 studies were on malaria, two were on a mix of malaria and pneumonia, one was on paediatric fever management, and one was on respiratory tract infections of viral or bacterial aetiology. Study designs included nine randomised controlled studies, four controlled, non-randomised studies, five uncontrolled interventions, one interventional pre-post study, one cross-over interventional study and three retrospective analyses of RCTs. Hansen et al. (2017) was a cost-effectiveness analysis of Mboyne et al. (2015)’s malaria study [26, 34].
Table 1.
Study information and characteristics
| Ref no | First author | Country | Year performed | Year published | Length of study (months) | Type of study | Name of POCT | Targeted disease | Targeted pathogen or antibody | Patient sample used for test |
|---|---|---|---|---|---|---|---|---|---|---|
| [23] | Ansah | Ghana | 2011 to 2013 | 2015 | 18 | Clustered randomized (RCT) | CareStart Malaria HRP2 Pf | Malaria | Plasmodium falciparum | Blood |
| [35] | Audu | Ghana | 2014 | 2016 | 6 | Prospective cross-over study | Blue Aid Malaria Test Kit | Malaria | P. falciparum, Plasmodium vivax | Blood |
| [36] | Aung | Myanmar | 2013 | 2015 | 6 | Clustered randomized (RCT) | Malaria POCT (unnamed) | Malaria | P. falciparum | Blood |
| [24] | Awor | Uganda | 2011 to 2012 | 2014 | 13 | Controlled but non-randomised study | Malaria POCT (unnamed) and respiratory timers | Malaria and pneumonia | NA |
Malaria: blood Pneumonia: breathing rate |
| [37] | Awor | Uganda | 2011 to 2012 | 2015 | 13 | Controlled but non-randomised study | Malaria POCT (unnamed) and respiratory timers | Malaria and pneumonia | NA |
Malaria: blood Pneumonia: breathing rate |
| [38] | Cohen | Uganda | 2011–2012 | 2012 | 13 | Interventional study without controls | Care Start Malaria HRP2 Pf | Malaria | P. falciparum | Blood |
| [26] | Hansen | Uganda | 2011 | 2017 | 12 | Cost effectiveness analysis of an RCT (see Mboyne et al.) | Care Start Malaria HRP2 Pf | Malaria | P. falciparum | Blood |
| [39] | Hutchinson | Uganda | 2010 to 2012 | 2015 | 22 | Clustered randomized (RCT) | Malaria POCT (unnamed) | Malaria | NA | Blood |
| [40] | Hutchinson | Uganda | 2010 to 2012 | 2017 | 22 | Clustered randomized (RCT) | Malaria POCT (unnamed) | Malaria | NA | Blood |
| [41] | Ikwuobe | Nigeria | 2012 | 2013 | 3 | Controlled but non-randomised study |
SD BIOLINE Malaria Antigen Pf |
Malaria | P. falciparum | Blood |
| [42] | Kitutu | Uganda | 2013 to 2015 | 2017 | 16 | Controlled but non-randomised study | Care Start Malaria HRP2 Pf and respiratory timers | Malaria, pneumonia and bloody diarrhoea | P. falciparum |
Malaria: blood Pneumonia: breathing rate |
| [43] | Kwarteng | Ghana | 2013 | 2019 | 8 | Interventional study without controls | Care Start Malraria HRP2 Pf | Malaria | P. falciparum | Blood |
| [44] | Maloney | Tanzania | 2013 to 2014 | 2017 | 15 | Clustered randomized (RCT) | ParaHIT Ag Pf POCTs | Malaria | P. falciparum | Blood |
| [34] | Mbonye | Uganda | 2011 | 2015 | 12 | Clustered randomized (RCT) | Malaria POCT (unnamed) | Malaria | NA | Blood |
| [33] | Mbonye | Uganda | 2011 | 2015 | See Mboyne 2015 | Policy analysis of Mboyne (2015) | ||||
| [45] | Onwunduba | Nigeria | 2022 | 2023 | 6 | Cluster randomized trial (RCT) | CRP test kit from Zhuhai Encode Medical Engineering Co | Respiratory tract infections (RTI) | Viruses or bacteria causing RTIs | Blood |
| [46] | O' Meara | Kenya | 2014–2015 | 2016 | 11 | Factorial randomized (RCT) | Malaria POCT (unnamed) | Malaria | NA | Blood |
| [47] | Poyer | Kenya | 2013–2016 | 2018 | 18 | Interventional pre-post study | CareStart Malaria HRP2 (Pf) | Malaria | P. falciparum | Blood |
| [48] | Shelus | Uganda | 2021 | 2023 | 3 months | Uncontrolled interventional trial | 8 types of RDTs, most frequently: SD Bioline, SD Biosensor, Carestart, and First Response | Malaria | P. falciparum | Blood |
| [49] | Simmalavong | Laos | 2008–2016 | 2017 | 108 | Interventional study without controls | Malaria POCT (unnamed) | Malaria | NA | Blood |
| [50] | Soniran | Ghana | 2019–2020 | 2022 | 14 | Cluster randomized trial (RCT) | Malaria POCT (unnamed) | Malaria | NA | Blood |
| [51] | Sudhinaraset | Myanmar | 2013 | 2015 | 6 | Qualitative study of RCT | FIRST RESPONSER Malaria antigen pLDH/HRP2 combo card test | Malaria | NA | Blood |
| [52] | Thet | Myanmar | 2019–2020 | 2021 | 3 | Interventional study without controls | Malaria POCT (unnamed) | Malaria | P. falciparum | Blood |
| Ref no | Urban/Rural | Type and number of outlets included in study groups | Description of clientele served by private stores selling POCT included in study | Sharp box and/or gloves provided? | Length and content of provider training | Guidelines for patients that test positive | Guidelines for patients that test negative | Supervision frequency and method of private providers of POCT | Demand generation activities | Recommended retail price of POCT |
|---|---|---|---|---|---|---|---|---|---|---|
| [23] | Rural | 24 communities with 1 to 5 chemical shops per community | Clients with fever or who requested antimalarials, who were not pregnant, > 6 months old, no severe disease, no prescription from health facility, in district for > = 28 days | Bins for disposal of sharps, reference charts for doses of artemisinin therapy |
3 days on Ghana’s antimalarials policy, symptoms, indications for referral, blood sampling, blood safety, sharps usage, infection prevention, study protocol Intervention arm: extra 1 day, how to perform, interpret and manage negative POCTs, practise sessions |
Encourage clients to purchase ACTs | Refer to nearby healthy facility or facility of choice | Recorded by seller on customised form which was subject to random checks by study authors; mystery clients | Community sensitization meetings and durbars (traditional community leaders) | NA |
| [35] | Mixed | 6 private retail pharmacies in 3 different districts of the Ashanti region | 1200 patients with fever or history of fever in past 48 h | No | Technique and usage of POCT | NA | NA |
Recorded by pharmacy on reporting form, which was studied daily by principal researcher; Microscopy to confirm diagnoses |
NA | NA |
| [36] | Rural | 171 general retail stores, drug vendors, medical drug representatives | Households who had fever in last 3 weeks and taken antimalarials or had malaria symptoms, lived in an area where ACT was sold in private sectors | Antiseptic pad provided | Use, interpretation and safe disposal of POCT | Prescribe ACT | Refer to nearest health facilities | Arm 1: Monthly check-in visit, Arm 3: Bi-monthly intensive support visits with one-on-one discussions, information, education and communication | NA | Price subsidy for POCT resupply at $0.18/test |
| [24] | Rural |
Intervention: 44 registered drug shops Control: 40 registered drug shops |
Caretakers and children (< 5y/o and febrile) who sought care in drug shop or lived in participating districts | No | 5 days of 2 drug shop attendants per drug shop on how to use POCT for fevers and respiratory timer for coughs, dispense pre-packaged drugs, via clinical sessions | Dispense recommended treatment of ACTs (malaria) and amoxicillin (pneumonia) | NA | Direct observation by field supervisor (nurse) | Branding of drug shops, communicating with caretakers of children, information on care-seeking provided at markets, public gatherings and radios | Free POCTs; Subsidised drugs: ACTs, amoxicillin, oral rehydration solution, zinc sulfate at 50–80% mark-up, selling at USD 0.38 |
| [37] | Rural |
Intervention: 44 registered drug shops Control: 40 registered drug shops |
Caretakers and children (< 5y/o and febrile) who sought care in drug shop or lived in participating districts | No | 5 days of 2 drug shop attendants per drug shop on how to use POCT for fevers and respiratory timer for coughs, dispense pre-packaged drugs, via clinical sessions | Dispense recommended treatment of ACTs (malaria) and amoxicillin (pneumonia) | NA | Direct observation by field supervisor (nurse) | Branding of drug shops, communicating with caretakers of children, information on care-seeking provided at markets, public gatherings and radios | Free POCTs; Subsidised drugs: ACTs, amoxicillin, oral rehydration solution, zinc sulfate at 50–80% mark-up, selling at USD 0.38 |
| [38] | Mainly rural | 92 drug shops in 58 villages that offered POCTs after completing training and households in the selected villages | Households in 67 villages with at least 1 pharmacy | Gloves and sharps disposal box provided | 2 days (adapted from a WHO-based organization) on POCT, administration procedures, results interpretation | No specific instruction was provided other than proceed as usual | No specific instruction was provided other than proceed as usual | Monthly monitoring visit with administrative record checks from wholesale distributors | NA | Shops bought it from wholesalers at an agreed US 0.20 and sold at shop’s discretion |
| [26] | Mainly rural | 20 randomized clusters, with10 for each intervention arm | Population with a majority living in rural areas/farmers seeking care for fever | No | 3 days on malaria case management, 1 extra day for intervention arm on POCT | Recommend ACT purchase | No ACT or other anti-malarials would be sold | Close support visit for first 3 months, lessened after | Community sensitization programs | POCTs provided to drug shops for free. Recommended retail price was $0.20 |
| [39] | NA | Registered drug shop vendors, residents in area around drug shop who were clients or cared for clients, health workers in area | Participants who had been to the drug shop or cared for someone who had been | Blood slides and slide box, gloves, lancets, swabs and cotton wool provided |
Both arms: 3 days on malaria, taking blood samples Intervention arm: 1 more day on POCTs |
NA | NA | 2 months of supervision of at least 3 supervisory visits; scaled back later with periodic contact; one more visit at 12 months | Roadside sign advertising POCT availability | Free |
| [40] | NA | 59 registered drug shops | Participants who had been to the drug shop or cared for someone who had been | Blood slides and slide box, gloves, lancets, swabs and cotton wool provided |
Both arms: 3 days on malaria, taking blood samples Intervention arm: 1 more day on POCTs |
NA | NA | 2 months of supervision of at least 3 supervisory visits; scaled back later with periodic contact; one more visit at 12 months | Roadside sign advertising POCT availability; community sensitization through Village Health Teams | Given for free and asked to sell at 0.20 USD |
| [41] | Suburban |
Intervention: 1 pharmacy with sufficient anti-malarial sales per day (> = 23 per day) Control: 1 pharmacy |
Patients with symptoms of malaria seeking malaria treatment (with an anti-malarial prescription or wanting to self-medicate with them) | No | How to conduct POCTs | Permit purchase of antimalarial | Pharmacist and patient would discuss to suspend anti-malarial treatment | NA | NA | NA |
| [42] | Mixed—Rural (6), Suburban (12), Urban (14 stores) |
Intervention: 61 drug shops Control: 23 drug shops |
Care seekers for children (< 5 y/o) with symptoms | No | Provision of information on workflow, information/education, communication on malaria, pneumonia, non-bloody diarrhoea treatments | Provide ACT (malaria) or amoxicillin DT (pneumonia) | Further evaluation and referral | Monthly supervision by supervisor trained in medicine, may be accompanied by district drug inspector and educator | Marking of intervention drug shops with posters, community sensitization campaign via radio talks | Free |
| [43] | Rural | 3 pharmacy shops, 68 licensed chemical shops | Clients with fever or malaria signs/symptoms without signs of severe malaria | Gloves, disposal bins provided | 1 week workshop on malaria treatment, POCT administration and counselling of results | Dispense ACT | Symptomatic treatment, return advice, withhold ACT | Bimonthly supervisory visits | NA | Free to drug shops. No recommended retail price |
| [44] | Rural |
Intervention: 1 subsidised districts with 147 accredited drug dispensing outlets (ADDOs), 1 unsubsidised district with 115 ADDOs Control: 1 district |
18 y/o customers seeking treatment for fever, suspected malaria, or trying to purchase anti-malarial | Gloves, sharps box provided | Six two-day trainings on recognising malaria, use of POCTs, and treatment | Prescribe ACT based on Artemether and lumefantrine treatment based on provided dosing reference chart | Referral of severely ill patients to nearest public health facility | Quarterly monitoring visits, during which dispenser was observed directly by study staff and shop conditions were evaluated | Storefront sign advertising malaria testing | Non-subsidised: 0.67 USD, Subsidised: < = 0.32 USD |
| [34] | Urban and periurban | 59 drug shops | Febrile patients seeking treatment at drug shops | No |
3 days for general malaria-related training Intervention arm: 1 extra day for POCT usage, blood slices preparation with extra training on communication skills to explain POCT diagnostics |
Prescribe ACT | POCT-negative cases with fever: consider referral, no ACT/antimalarials would be sold | 2-month period of supervision with at least 3 supervisory visits, 12-month follow-up | Signs placed outside for advertisement, community sensitization programs prior to trial | POCTs provided for free. Priced at $0.20 |
| [33] | ||||||||||
| [45] | Urban | 20 private community pharmacies (10 intervention, 10 control) | Simulated clients who were trained to visit the pharmacy and complain of particular RTI symptoms | NA |
Length was not described Training on use of CRP test kits and distinguishing viral and bacterial etiologies based on test kits |
Advised not to dispense antibiotics to those with CRP < 30 mg/l, to use clinial judgments for CRP levels 30 ≤ CRP < 100 mg/l, dispense antibiotics if CRP ≥ 100 mg/l, but not discouraged from using professional judgement regardless of CRP results | Mystery clients visiting the pharmacies and presenting with RTI-like symptoms | NA | RDTs were provided and pharmacies were asked to charge < 1 USD per test | |
| [46] | Rural | 11 medicine shops | Any individual < 1 years old with malaria-like illness or symptoms during past 24 h | No | 3 days on how to perform POCT | NA | NA | Field visits 1 week after enrolment of patients | NA | Yes, either free or $0.50 depending on group |
| [47] | Mixed | 317 outlets (142 private health facilities and 175 pharmacies) | Adults seeking treatment for fever for themselves or on behalf of someone else | Gloves and sharps box provided | Training on malaria epidemiology, POCT procedure, case management for positive and negative test results | Prescribe ACT | Private health facilities—further investigatino, pharmacies—referral to health facility | routine supportive supervision visits | Radio, printed materials, small group sessions to highlight that not all fevers are malaria | 0.80 USD for POCT from hospital pack, 1 USD for POCT single pack |
| [48] | Rural | 46 drug shops in 20 villages | Clients visiting participating drug shops reporting fever or purchasing antimalarials for themselves or other individuals | Not specified but given "materials to safely collect blood samples and dispose of waste" | 90 min training on study and RDT procedures | NA | Na | NA | NA | NA |
| [49] | Urban | 317 pharmacies, 30 clinics | NA | NA | NA | NA | NA | NA | NA | NA |
| [50] | Rural | 12 over-the-counter medicine sellers (7 intervention, 5 control) | Children under 10 years old with fever or suspected malaria in nearby households | NA | 2 day training on malaria management, treatment and follow-up | Provide ACT | NA | Quarterly supportive visitis during which skills from training were reinforced and technical guidance was provided | Community health workers and town criers engaged to carry out sensitization on malaria highlighting the imporance of malaria testing before treatment at religious venues and community durbars | 0.44 USD |
| [51] | Rural | 30 informal providers | NA | NA | NA | NA | NA | NA | NA | NA |
| [52] | Urban | 80 malaria drug shops for quantitative, 65 of these for qualitative interviews | Patients who were febrile and seeking care and drug shops | No | 1 day on use of POCT, national guidelines on treatment, stock and waste management, counselling, reporting to national centres | “Effective and quality” antimalarial drugs | Antipyretics, analgesics, medicines, but not antibiotics | NA | NA | NA |
Studies lasted between three [41, 52, 53] and 108 months [49]. Of the studies where the setting of the study was described, nine were in rural areas [23, 24, 26, 36–38, 43, 44, 46, 50, 51, 53], five in urban/suburban regions [33, 34, 41, 45, 49, 52], and two were in a mix of both [42, 47]. The number of outlets investigated per study ranged from two [41] to 317 [49].
Only eight studies described the consumable equipment they provided to the private retailers, like antiseptic pads [36], free gloves and sharps disposal [23, 38, 44, 47], or bins [39, 40, 43]. 20 studies implemented training for providers, covering study protocol, signs/symptoms, evaluation, and diagnostic criteria. Intervention arms also received training on POCT administration, interpretation, and disposal. Training lasted between 90 minutes [53] and six 2-day sessions [44].
For malaria, guidance for patients testing positive were provision of the appropriate medication, such as ACTs for malaria [23, 24, 26, 34–37, 41–44, 47, 52]. For other POCTs, patients satisfying disease criteria based on the test results were supposed to be prescribed amoxicillin for pneumonia [24, 37, 42], antibiotics for CRP levels greater than or equal to 100 mg/l [45], or zinc sulfate tablets for non-bloody diarrhoea [42]. For negative test results, clients were often referred to formal care [23, 36, 42, 47], especially if there was fever [34]. Sellers were to recommend stopping antimalarials [41] or against their purchase [24, 26, 34, 37, 43], or in cases of CRP less than 30 mg/l, to not dispense antibiotics [45]. Kwarteng et al. (2019) provided symptomatic treatment [43]. In Onwunduba et al. (2022), cases with CRP of intermediate levels between 30 mg/l to 100 mg/l, sellers were asked to use their professional judgment to decide on prescription of antibiotics [45].
Demand-generation activities were paper-based like roadside posters, media-based like newspapers or radio, and/or verbal promotions during healthcare consultations or durbars held by traditional community leaders [23].
Methods of assessing outcomes
Table 2 summarises study methodologies.
Table 2.
Studies’ methods for assessing outcomes
| STUDY METHODS | ||||||||
|---|---|---|---|---|---|---|---|---|
| Ref no | First author | Year published | Targeted disease | Safety and accuracy of POCT administration | Accuracy of POCT | POCT testing: uptake, positivity | Treatment decision | Retail price method |
| [23] | Ansah | 2015 | Malaria | Mystery clients were directly observed weekly in 1st month and for 1 more week halfway through trial; regular quality control by sampling test kits using positive blood samples | NA | Recorded by seller in study-customized recording form; blood samples collected in both arms | Recorded by seller in study-customized recording form | NA |
| [35] | Audu | 2016 | Malaria | NA | NA | Recorded by seller | Recorded by seller | NA |
| [36] | Aung | 2015 | Malaria | Mystery client | NA | Household surveys; Mystery client interview | NA | NA |
| [24] | Awor | 2014 | Malaria and pneumonia | Direct observation by field supervisor (nurse) | NA | Exit interviews; household survey; direct observation | Exit interviews | NA |
| [37] | Awor | 2015 | Malaria and pneumonia | Direct observation by field supervisor (nurse) | NA | Exit interviews; household survey; direct observation | Exit interviews | NA |
| [38] | Cohen | 2012 | Malaria | NA | Initial report by WHO/FIND on POCT test, checked every 3 months with 4 unused tests sent for testing | Sales data, administrative records from wholesale distributor, household surveys | Household surveys | NA |
| [26] | Hansen | 2017 | Malaria | NA | Microscopy of on-site blood slides | Pharmacy records and surveys | Pharmacy records | Prior willingness to pay study |
| [39] | Hutchinson | 2015 | Malaria | No quantitative data | NA | NA | NA | Given for free, can do what they want |
| [40] | Hutchinson | 2017 | Malaria | No quantitative data | NA | Information recorded by drug seller and then follow up interviews with questionnaires to clients | Information recorded by drug seller and then follow up interviews with questionnaires to clients (i.e. not based on pharmacy records alone) | Fixed by study authors |
| [41] | Ikwuobe | 2013 | Malaria | NA | Batch testing replicating field conditions | Epi-Info version 7 questionnaire | NA | Free |
| [42] | Kitutu | 2017 | Malaria, pneumonia and bloody diarrhoea | Direct observation every month | NA | Pharmacist records, exit interviews, direct observation | Pharmacist records, exit interviews, direct observation | NA |
| [43] | Kwarteng | 2019 | Malaria | POCT results independently confirmed by lab technician 1 h after results | NA | Participants' questionnaire, focus group discussion, in-depth interview | Participants' questionnaire, focus group discussion, in-depth interview | NA |
| [44] | Maloney | 2017 | Malaria | NA | NA | Outlet surveys, customer exit interviews | Customer exit interviews | Willingness to pay responses from pre-intervention exit interviews, comparison w analogous commodities, price negotiation with wholesalers |
| [34] | Mbonye | 2015 | Malaria | NA | Used mPOCTs results were routinely checked by research team, confirmed with microscopy testing of blood samples | Vendors recorded data into a specific register | Vendors' data, follow-up interview on 4th day post-visitation | Willingness-to-pay study prior to intervention |
| [33] | Mboyne | 2015 | ||||||
| [45] | Onwunduba | 2023 | Respiratory tract infections | NA | NA | Mystery clients themseleves recorded data on the visit on structured data collection form | Mystery clients themseleves recorded data on the visit on structured data collection form | RDTs were provided and pharmacies were asked to charge < 1 USD per test |
| [46] | O' Meara | 2016 | Malaria | NA | NA | Customized electronic data collection form | Customized electronic data collection form | NA |
| [47] | Poyer | 2018 | Malaria | Direct observation by supervisors, mystery client visits | NA | Client exit interviews, mystery client visits | Client exit interviews, mystery client visits | NA |
| [48] | Shelus | 2023 | Malaria | NA | NA | Drug shop vendors completed data collection form for each eligible client | Drug shop vendors completed data collection form for each eligible client | NA |
| [49] | Simmalavong | 2017 | Malaria | NA | NA | NA | NA | NA |
| [50] | Soniran | 2022 | Malaria | Mystery client | NA | Pre and post-intervention household surveys; mystery client surveys | Pre and post-intervention household surveys; mystery client surveys | NA |
| [51] | Sudhinaraset | 2015 | Malaria | NA | NA | NA | NA | NA |
| [52] | Thet | 2021 | Malaria | Survey of drug shop providers | NA | Survey of drug shop providers | Survey of drug shop providers | NA |
Studies collected data on POCT implementation and/or treatment decisions by forms/questionnaires filled out by drug vendors [23, 34, 35, 41, 46, 50, 53], direct observation of the vendors or mystery clients [24, 36–38, 42–45, 47, 52]. Patient-based methods included sales data, administrative/patient records [26, 38] or provider/household surveys [24, 36–38, 44, 50, 52]. Simmalavong et al. (2017) used epidemiological data [49]. Qualitative methods included focus group discussions [39, 40, 43] or interviews with providers [51, 52].
To assess accuracy of POCT administration, studies used mystery clients [23, 36, 45, 47], direct observation [24, 37, 42, 44], microscopy of blood slides [18, 34, 43], or checking POCTs [43]. Two studies reported manufacturer’s specificity and sensitivity [23, 35]. Three assessed sensitivity and specificity directly by comparing malaria POCT results to blood microscopy [26, 34, 41]. Cohen et al. (2012) randomly checked unused tests [38].
Few studies reported how they determined retail price if authors recommended a specific price. Three malaria studies referenced previous willingness-to-pay studies [26, 34, 44].
Testing and treatment outcomes
In general, studies showed that implementation of POCT could lead to feasibly high uptake levels and adherence to treatment guidelines (Table 3).
Table 3.
Outcomes of testing and treatment
| Ref no | First author | Year published | Sample size | Intended treatment for the Targeted Disease | Description of intervention arm(s) | POCT uptake | POCT positivity (% of patients receiving an POCT who tested positive) | Treatment provision: proportions of all study participants receiving treatment(s) intended for those testing positive |
|---|---|---|---|---|---|---|---|---|
| [23] | Ansah | 2015 | 4603 clients attending 24 clusters of shops (each containing 1 to 5 shops) | Artemisinin combination therapy: amodiaquine-artesunate, arthemeter-lumefantrine, or dihydroartemisinine-piperaquine | Shops were trained to carry out a malaria POCT before dispensing medication | 100% | 49.70% |
Based on POCT results: 78.8% (2142/2719, based on POCTs) 65.3% (3005/4603, based on research slides) |
| [35] | Audu | 2016 | 1200 at 6 private retail pharmacies | Artemether-lumefantrine | Shops were trained on the use of malaria POCT before dispensing medication | NA | 43% |
Control arm: 98.2% Intervention arm: 78.3% (100% of those of tested positive and 62% of those who tested negative) |
| [36] | Aung | 2015 | 832 fever cases at 631 POCT outlets | Antimalarials | Arm 1: price subsidy for POCT resupply and monthly check-in visit. Arm 2: price subsidy for POCT and financial/product-related incentives. Arm 3: price subsidy for POCT and monthly intensive support visits by health officers |
Arm 1: from 3.0% to 6.4% Arm 2: from 2.7% to 11.9%, Arm 3: from 5.4% to 13.0% |
NA | NA |
| [24] | Awor | 2014 |
Intervention: 487 children with fever at across 44 shops Control: 275 children with fever across 40 shops |
Antimalarials for malaria or amoxicillin, oral rehydration solution and zinc sulfte tablets for pneumonia | Shops were trained and provided with subsidised diagnostics and drugs and a community awareness campaign, following “integrated community case management”-style intervention | From 0% to 87.7% of children with fever (427/487) | 75% (44/47, based on direct observation) |
70.4% (343/487, based on exit interviews) 70.2% (33/47, based on direct observation) |
| [37] | Awor | 2015 | 6140 children with fever across 44 shops | Antimalarials, oral rehydration solution and zinc sulfte tablets for pneumonia | Shops were trained and provided with subsidised diagnostics and drugs and a community awareness campaign, following “integrated community case management”-style intervention | 97.5% of children with fever (5986/6140) | 85.1% (5096/5986) | 85% (5218/6140) |
| [38] | Cohen | 2012 | 58 villages offering POCTs (87% of total number of villages) | Artemisinin-based combination therapy or other antimalarials | Shops were trained on tests and told to proceed as they would normally based on whether they thought the client had malaria or not after the test | 16% of those with fever | 89% |
ACT 32% of those testing positive 9% of those testing negative 26.4% of those not tested at all Other antimalarials 66.4% of those testing positive 33.3% of those testing negative 35% of those not tested at all |
| [26] | Hansen | 2017 | 7522 in intervention, 5797 in control arm | Artemisinin combination therapy | Drug shops trained on how to perform and interpret malaria POCT and prescribe subsidised ACT based on POCT results | 100% | 43.50% |
Intervention: 61% Control: 100% |
| [39] | Hutchinson | 2015 | 21 focus group discussions (no info on how many people per focus group) 12 months after implementation | Artemisinin combination therapy | Drug shops were trained on POCT usage and decided to treat based on results of POCT | |||
| [40] | Hutchinson | 2017 | Staff from 59 drug shops, divided into 21 focus groups (each having btw 5 to 13 participants) | Artemisinin combination therapy | Pharmacies were trained to recognise malaria based on POCTs and decide to treat based on the POCT outcome | 97.60% | 57.50% | 52.70% |
| [41] | Ikwuobe | 2013 | 619 patients in intervention, 607 in contorl, btw 2 pharmacies; total of 1226 participants | Antimalarials | Pharmacists were trained on and provided with POCTs and tested those with anti-malarial prescription or wanting to self-medicate with them, then allowed to proceed with dispensing of drugs following discussion between pharmacist and patient | NA | 13.6% (84/619) | 58.2% (360/619) |
| [42] | Kitutu | 2017 | 3738 child fever cases across 61 drug shops in intervention arm | Artemisinin for malaria, amoxicilllin for pneumonia, zinc sulfate solution for non-bloody diarrhoea | Drug shops were trained in integrated community case management to provide POCT testing for children with malaria, consisting of training of drug sellers, provision of information, education and communication, supplying diagnostics and medicines, and monthly supportive supervision | 97% (3628/3738) | 47% (1957/4190) | NA |
| [43] | Kwarteng | 2019 | 1973 clients across 42 licensed chemical shops | Antimalarials | Pharmacies and licensed chemical shops were trained on use of malaria POCTs and treated based on national malaria treatment guidelines | NA | 60.2% (1081/1797) | 60.2% (1082/1797) |
| [44] | Maloney | 2017 | 1214 patients across 262 drug dispensing outlets | Antimalarials |
Arm 1: training, access to and supervision on use of POCTs to treat clients Arm 2: same as Arm 1 but also received subsidised POCTs and sold at subsidized price |
Intervention: increased from 19 to 74%, cntrol: increased from 3 to 18% | 41% | NA |
| [34] | Mbonye | 2015 | 15517 patients (8672 intervention and 6845 control) across 59 drug shops | Artemisinin combination therapy | Drug shops were additionally trained on use of malaria POCT, and asked to manage patients based on POCT results using subsidized ACT | 97.8 | 58.50% |
Intervention: 62.5% Control: 99.8% |
| [33] | Mboyne | 2015 | Policy implications of Mboyne et al. (2015) | |||||
| [45] | Onwunduba | 2023 | ||||||
| [46] | O' Meara | 2016 | 444 participants across 11 shops | Artemisinin combination therapy |
Arm 1: Free POCT and conditional ACT subsidy Arm 2: Free POCT but no ACT subsidy Arm 3: No POCT subsidy but conditional ACT subsidy Arm 4: No POCT or ACT subsidy |
Arm 1: 73.7% Arm 2: 73.8% Arm 3: 49.6% Arm 4: 51.0% |
Arm 1: 39.3% Arm 2: 27.6% Arm 3: 44.6% Arm 4: 47.1% |
Arm 1: 43.9% Arm 2: 25.9% Arm 3: 32.8% Arm 4: 29% |
| [47] | Poyer | 2018 | 633 clients in second round at 120 outlets, but high rates of dropout | Antimalarials | Private health facilities (PHF) and pharmacies (P) were trained in use of malaria POCTs and offered them to febrile patients |
PHF: from 30.4% to 52.6% P: from 52.1% to 56.3% |
PHF: from 52.3% to 45.1% P: from 47.2% to 52.8% |
PHF; from 42.5% to 41.8% P: from 31% to 29.4% |
| [48] | Shelus | 2023 | 934 clients of drug shops | Antimalarial | Drug shops offered malarial POCTs to febrile clients or clients seeking antimalarials for themselves or for others and recorded the medication purchased by these clients | 36% | 43% | 79.40% |
| [49] | Simmalavong | 2017 | 2,301,676 tests across 317 pharmacies | Artemether/lumefantrine | Private pharmacies were trained on and supplied with POCTs and antimalarials to diagnose and treat malaria as part of a public–private scheme to increase diagnostics in private clinics, which was then scaled up over time | NA | ||
| [50] | Soniran | 2022 | 637 caregivers of febrile children under 10 yo and 48 mystery cleint visits | ACT | Over-the-counter medicine selllers were trained to sight patients suspected of malaria and conduct a test on thembefore prescribing antimalarials to patients testing positive | 30.8% (intervention; household survey) or 38.1% (intervention; mystery client); 10.5% (control; household survey) or 23.3% (control; mystery client) | 25.0% (intervention, mystery client) vs 42.9% (control, mystery client) | 33.3% (intervention, mystery client) vs 53.3% (control, mystery client) |
| [51] | Sudhinaraset | 2015 | 30 informal providers of POCTs | Antimalarials |
Arm 1: subsidised POCTs Arm 2: subsidised POCTs and free POCT for every 5 purchased by providers Arm 3: subsidised POCTs and information, education and counselling |
NA | ||
| [52] | Thet | 2021 | 80 malaria drug shops for quantitative and 65 of these for qualitative interviews | "Effective and quality" antimalarial drugs | Drug shops participated in nationwide project to replace widespread use of artemisinin monotherapy with combination therapy, and were trained to perform malaria POCT to guide management of clients | NA | NA | NA |
| Ref no | Treatment provision: % of patients not tested receiving the intended treatment for the study's targeted diseases | Adherence: % of patients with a negative POCT result not receiving the intended treatment for the study's targeted diseases | Adherence: % of patients with a positive POCT result receiving the intended treatment for the study's targeted diseases | % of patients tested positive referred elsewhere by the provider for further care | Safety & Accuracy of administration of testing (% of providers who could accurately perform an POCT, read its result and dispose of waste) | Accuracy of POCT (sensitivity, specificity, positive predictive value or other quality measures) | Retail price (USD) |
|---|---|---|---|---|---|---|---|
| [23] | Control: 93% (slide-positive), 88% (slide-negative) | 97% | 99.50% | 0.52% (7/1351) | 87.2% to 100% of different safety indicators |
Sensitivity: 98–100% by shop Specificity: 73% to 98%, some 30%, 31%, 52% |
0 |
| [35] | 98.20% | 38% | 100% | NA | NA |
Sensitivity: 97.3% Specificity: 98.5% Positive predictive value: 98.0% |
NA |
| [36] | NA | NA | NA | NA | 94% | NA | 0.18 |
| [24] | NA | 90.9% (10/11, based on direct observation) | 100% (33/33, based on direct observation) | NA | 94% | NA | 0 |
| [37] | NA | NA | 93.5% (4961/5307) | NA | NA | NA | NA |
| [38] | 61.40% | 57.70% | 98.40% | NA | > 95% for POCT administration and procedure adherence | Lot-testing: 100% passed | 0.40 (ranged between 0–2) |
| [26] | 100% | 98.60% | 99.10% | NA | NA |
Sensitivity: 91.75% Specificity: 62.92% |
0.2 |
| [39] | |||||||
| [40] | 99.20% | 70.30% | 94.30% | NA | NA | 2 (between 0.08–13.20 USD in mPOCT negative); 1.62 (between 0.12–12.80 USD in mPOCT positive); 1.32 (between 0.32–18.00 USD in control arm) | |
| [41] | Control: 100% (607/607) | 48.4% (259/535) | 100% (84/84) | NA | NA |
Sensitivity: 100% Specificity: 100% |
0 |
| [42] | NA | NA |
73.9% (based on exit interviews) 88.7% (based on pharmacist record) 63.3% (based on direct observation) |
NA | NA | NA | 0 |
| [43] | NA | 73.9% (529/716) | 82.79% (895/1081) | NA | 94.9% (1873/1973) | NA | NA |
| [44] |
Intervention: 35% Control: 41%l |
93% | 90% | NA | NA | NA | 0.32 (subsidised) and 0.67 (not subsidised) |
| [34] |
Intervention: 51.4%-73.7% Control: 99.6%-100.0% |
98.5% (3117/3166) | 99% (4858/4907) | NA | 95% of POCTs read correctly |
Sensitivity: 91.7% Specificity: 63.1% |
0.2 |
| [33] | |||||||
| [45] | |||||||
| [46] | Arm 1: 30%, Arm 2: 29.6%, Arm 3: 21.1%, Arm 4: 26.5% | Arm 1: 72.5%, Arm 2: 80.0%, Arm 3: 87.1%, Arm 4: 92.6% | Arm 1: 81.8%, Arm 2: 71.4%, Arm 3: 84%, Arm 4: 58.3% | NA | NA | NA | 0 or 0.50 |
| [47] |
PHF: from 8.4% to 19.8% P: from 40.8% to 22.2% |
PHF: from 93.3% to 96.1% P: from 86.1% to 100% |
PHF: from 84.6% to 91.6% P: from 86.8% to 92.6% |
0% |
PHF: from 25.3–97.8% to 14.7–100% P: from 33.3–100% to 20.7–97.7% |
0.8 or 1 for hospital or single pack POCT respectively (suggested prices) | |
| [48] | 87.30% | 63.70% | 93.60% | NA | NA | NA | 0.57 |
| [49] | |||||||
| [50] |
From 47.1% to 66.7% (before and after intervention, household survey) 34.6% (Intervention, mystery client) vs 52.2% (Control, mystery client) |
83.3% (Intervention, mystery client) vs 75.0% (Control, mystery client) | 75.0% (Intervention, mystery client) vs 100% (Control, mystery client) | NA | 66.7% (intervention, mystery client) vs 40% (control, mystery client) | NA | 0.44 |
| [51] | |||||||
| [52] | NA | 73.90% of drug shops | NA | NA | NA | NA | NA |
This was dependent upon factors like adequately designed training, demand generation, linkage to care, support for providers, and appropriate financial remuneration. For example, in one longitudinal study of malaria POCTs, uptake increased when monthly check-ins, financial incentives, or more intensive support was implemented in subsidized schemes of POCTs, from 3.0% to 6.4% (monthly check-ins), 2.7% to 11.9% (financial incentives), and 5.4% to 13.0% (intensive support) [36]. Moreover, six studies reported adherence of treatment outcome to positive and negative test results above 90% [23, 24, 26, 34, 44, 47]. These factors will be discussed individually below.
Training for providers
POCT implementation requires comprehensive training before implementation and our review finds that it should cover topics including POCTs’ importance and benefits, its administration, interpretation, waste disposal, and counselling after results [40, 54, 55]. Firstly, emphasising the need, value, and accuracy of POCTs may improve uptake. In a Kenyan malaria study that only taught epidemiology and POCT procedure/management but did not emphasise the need for POCTs, uptake was as low as 30.4% [47]. Conversely, when providers were educated on POCT’s value and felt aligned with professionals through training, higher provider uptake was observed [36, 51, 56, 57], reaching 97% in a study where drug shops were trained in an integrated community case management style where providers were educated on the need and how malaria POCTs worked [42]. Instilling belief in the need for POCTs could address other factors limiting POCT uptake – for example, some providers only used POCTs for specific patient profiles or disobeyed guidelines, believing NGOs had eradicated local malaria [51] or endemicity was declining [52]. Alternatively, some providers relied on clinical judgement if they perceived shortcomings of POCTs [35]. One study found poor adherence to negative malaria POCT results, as 20–41% of malaria-negative mystery clients were told by providers that they were positive and suggested that this was due to providers’ “mistrust of POCT results” despite their competence in POCT performance [47]. This is despite high sensitivity of malaria POCTs (91.7%–100% [23, 34]), which could be highlighted in training to instil confidence.
Secondly, training must include clear guidelines for negative tests. Studies with the worst adherence to negative test results – 48.4% in Ikwuobe et al. (2013) and 57.7% in Cohen et al. (2012), which also had the poorest uptake (16%) – had (sometimes deliberately) vague guidelines [38, 41]. The former lacked guidelines on handling negative results and suspension of antimalarials only after a pharmacist/patient discussion without study authors [41]. In the latter, staff were to proceed as “[they] would normally”, only being told “how POCTs work and how to use them” [38]. Hutchinson et al. (2017) reported vendors’ “anxiety around the management of a negative mPOCT [malaria POCT] result” as negative results might reveal “diagnostic uncertainty” regarding the illness, negatively impacting vendors’ reputation [40]. Hence, managing negative test results well is important for provider uptake and to reassure customers. This is also important from the providers’ perspective to maintain drug sales, which will be discussed below.
Guidelines for negative tests appear to be particularly important for diseases in which concerns about under prescription are dominant. Of studies with large discrepancies between adherence to positive versus negative test results, studies tended to report higher adherence to positive results than negative (Table 4) [35, 38, 40, 41, 53]. This could reflect a reluctance to under-prescribe medication and miss a diagnosis in malaria. In contrast, in other studies of notifiable diseases like HIV and HCV, low positive adherence may indicate stigma: for example, an HCV study in a high-income country (excluded from this review) reported 100% adherence to negative test results but only 28.2% adherence to positive test results [58]. However, data on this in the studies included in this review is limited, as the single study on CRP POCTs only reported adherence to negative CRP test results (30.4%) as they only collected data through mystery clients [45].
Table 4.
Studies where positive and negative adherence differ
Thirdly, providers should consider the format in which training is implemented. Certification of a formal training course could assure customers of providers’ credibility and instil self-confidence in providers, particularly in LMICs [26, 34, 39, 40]. For example, Klepser et al. mandated a “Collaborative Institutional Training Initiative program” and POCT certificate course [60–62]. This would capitalize upon the increased legitimacy in the eyes of customers already conferred upon vendors using POCTs. For example, customers were surveyed on their opinion of the outlets administering POCTs. In Uganda, POCTs gave legitimacy to vendors, who were perceived to have unclear credentials [33, 39] or purely profit-driven [40]. This change was attributed to the involvement of external project supervisors/government and new technology [39], with sharps and blood testing shifting vendors into the “category of an endorsed professional” [34, 40]. Such outward-projecting improvements in retailers’ image also benefited vendors: for example, in Uganda, vendors reported outward-directed benefits, as government partnership conferred legitimacy, status, and confidence about safety from authorities’ raids [39]. They attributed this to POCT technology marking them as endorsed professionals, particularly visibly drawing blood using recognisably medicalized objects like gloves, needles, and packaged lancets [39]. Hence, formalization of training and certification in POCT could reinforce these benefits and improve uptake amongst customers by legitimizing shops. Studies performed after the COVID-19 pandemic, in which pharmacists took on a big role in testing, might show further changes in this direction of customers’ attitudes toward pharmacist-performed POCT, as has been shown for high-income countries [63–66]. However, none of the studies performed after the pandemic directly assessed changes in these attitudes.
Some customers worried sellers were “unskilled” in the practice of POCTs and risked HIV infection [51] or injury, or overcharged [40]. In contrast to these concerns, six studies reported that POCTs were accurately performed, with performance of measures of safety/test administration/waste disposal above 90% [23, 24, 34, 36, 38, 43] and vendors felt more confident about making medical decisions by reducing guesswork [40, 51, 67]. However, a few studies like Poyer et al. (2018) reported more inconsistent levels of accuracy, between 14.7% and 100% attainment of safety outcomes [47], while Soniran et al., (2022) reported 66.7% attainment of safety outcomes compared to 40% in control arms [50]. Some commonly missed steps before the procedure included not checking expiry dates [38], explaining the test, or testing away from other clients [47]. Steps missed during the test were drawing the right amount of blood [38, 50], using antiseptic [36], wearing gloves [47], checking the time after adding the buffer [50]. Afterwards, providers failed to immediately dispose of lancets in sharps bins [47, 50], or waited < 15 min before reading the result [47]. We recommend that a checklist be provided, highlighting these commonly missed steps to ensure that the proper procedures are followed.
Demand generation and community sensitization
Community sensitization can help potential customers recognise the importance of POCT and appropriate treatment [24, 54, 57, 68]. Patients were more likely to consent to receiving a POCT if they had used one before or were aware of its availability [44]. For example, two studies in this review with the highest adherence to test results implemented a POCT program that integrated with a community awareness campaign [24, 37]. Conversely, lack of familiarity contributed poor uptake in some studies which lacked any demand generation [27, 69–71], as evidenced in studies like Cohen et al. (2012), and Ikwuobe et al. (2013). Community sensitization could improve customers’ acceptance of test outcomes and reduce pressure on providers to meet customers’ expectations, improving provider adherence too [47, 51]. Furthermore, some providers did not comply with national malaria guidelines as they could not ensure patients finished the full antimalarial course [52] – community sensitization could teach patients to receive treatment properly.
The content of sensitization should emphasize the benefits of testing at private retailers without diminishing other healthcare sectors: for example, a qualitative study suggested that sensitization efforts should focus on emphasising the need for testing regardless of the location (public or private), and leverage the trust in drug shops, which could increase uptake at private retailers without diminishing the work of public healthcare [59]. In the reviewed studies, over 80% of customers were satisfied with POCTs [34, 72–74], citing the convenience of testing locations [51, 74], as they would not have to travel to hospitals [40].
Programs need to consider the most effective methods of community sensitization, which may vary depending on the level of economic development or degree of trust in medical technology in the area. For example, two studies communicated the need for POCTs through community leaders, which may be better trusted by communities in LMICs [23, 50]. None of the included studies surveyed the participants on where they had heard of the POCT service, a question that could be included in future questionnaires to evaluate the most effective form of advertising.
Linkage to care
Several studies identified formal linkage to support as important for success. Barriers included resistance from healthcare workers to the POCT program [34] and failure of patients to honour referrals [43]. For example, health-workers were concerned about the same issues that were reported by private sellers as being beneficial to private retailers. They felt untrained vendors encroached on professional boundaries, deeming them untrustworthy, and did not acknowledge the paperwork vendors used to refer customers [39]. Health-workers also worried about decreased malaria testing at their facility [39]. However, some health-workers recognised improvements like customers’ shorter travel times [40].
Suggestions to bridge public and private sectors include capacity-building programs for pharmacists with health workers to address mistrust of health workers [43] or partnership with government agencies and professional bodies [47]. Community sensitization on accreditation of pharmacists and the formalisation of training could address health workers’ preconceptions about unprofessionalism [39]. Secure communication platforms should be established to protect data security. Two studies further proposed integrating POCT programs into nationwide malaria surveillance systems [44, 49].
Support for providers
Adequate provider supervision and support is important immediately after POCT implementation and in the long run. One study found price subsidies for providers to buy POCTs were most effective when accompanied by monthly intensive support as it led to a larger increase in uptake (from 5.4% to 13%) than just check-in visits (from 3% to 6.4%) [36]. Another study commented that prolonged support is necessary because provider behaviours, particularly for malaria, are “driven by ingrained behaviours” and thus difficult to change quickly [23]. This was echoed in focus group discussions with providers, as although some providers felt POCTs were easy to use and optimised workflow by reducing guesswork [51], others felt their workload had increased. However, adequate support and minimizing the Hawthorne effect need to be balanced [34]. The Hawthorne Effect can occur when practitioners modify their behaviour knowing that they are being monitored during interventional studies [34]. A possible support schedule could provide intensive support initially and decrease intensity over time [75, 76].
In LMICs, as well as individual provider support, other forms of support that should be considered in POCT implementation programs include addressing systems-level barriers [51, 77]. Providers relied on research teams for waste disposal or struggled to collaborate with public health facilities [51, 77]. Hence, this study recommends that a systematic approach to integrating private retailers into waste management systems and infrastructure be considered for safe POCT disposal.
Other systemic factors relating to procurement included lacking weighing scales to calculate antimalarial dosage [43], or being undeliverable due to flooded roadways [44]. Simmavalong et al. (2017) described private facilities’ lack of control over POCT distribution left them vulnerable to “trickle down shortages” in their government-led program [49]. In one study, some shops disobeyed malaria guidelines as they lacked POCTs (3/65) or antimalarials (1) despite free central provision [52]. When designing POCT programmes in LMICs, comprehensive material and logistical support in addition to the POCTs themselves needs to be included.
Financial remuneration and pricing
POCT pricing should be carefully evaluated through willingness-to-pay studies, as it impacts provider income and patient uptake. Factors like manufacturing subsidy, distribution, cost of training, equipment, or supervision should be balanced against the price customers are willing to pay. Especially in LMICs, where the “combined cost of mPOCT [malaria POCT] and ACT is a barrier to rural folks” [43], a subsidy may be necessary to facilitate patient uptake.
Seven studies offered POCT for free to customers [23, 24, 35, 37, 41, 43, 46], while seven supplied POCT for free but sold at a subsidized price [26, 34, 38, 40, 44, 46, 47, 50], and the remaining studies did not explicitly state the price at which they were sold [35, 43, 49, 51, 52]. In Hutchinson et al. (2015), providers were given tests for free and sold at providers’ chosen price [39]. Retail prices for customers ranged between 0.18 USD (Myanmar [36]) to 2 USD (Uganda [40]).
These different financial schemes have been evaluated to mixed results – in one malaria study, there was no difference in uptake between districts that were or were not subsidised for POCTs [44]. Similarly, providing another financial incentive in addition to price subsidies did not significantly increase uptake compared to price subsidy with intensive support [36]. In contrast, a third study reported malaria POCT subsidies positively impacted uptake independent of a prior offer of an antimalarial subsidy, suggesting that subsidies influence the “next immediate action” (deciding whether to test) [46]. A cost-effectiveness analysis of malaria POCT in Myanmar also found that price subsidy coupled with information, education and communication provider-targeted strategy was the most cost-effective [78]. Possible cost-saving measures included reducing supervision, having shops cover some training fees or gloves.
Providers’ attitudes towards renumeration may be affected by disease endemicity and negative test management. For illnesses like malaria where negative tests could impact drug sales directly, there was “tension between the motivation of the shop owner to make a profitable drug sale” and the lack of income after a negative test [46]. This was echoed in Gwagwalada, Nigeria, considered meso-endemic for malaria, where reduced antimalarial purchase may generate significant income loss [41]. A pharmacist “expressed concerns about loss of sales”, reasoning it would be difficult to restrict profit-guided pharmacies’ antimalarial sales without alternative income [41].
In studies with high malaria positivity, providers felt the programme benefited from them financially, as they enjoyed increased drugs and POCT sales [24, 39]. Even negative tests offered opportunity to sell more drugs, changing from antimalarials to other drugs like antipyretics [23, 26], and greater polypharmacy and median spending by those testing negative [40]. However, drugs like paracetamol have a “lower profit margin”, so whether overall economic benefit occurs may be affected by the proportion of positive/negative tests in high/low endemic areas [37]. These further highlight the importance of providing clear guidelines for negative test results, as described earlier.
Quality assessment
Study quality varied greatly (Table 5): only 11 studies had a randomised research design and a control group, of which seven corrected for confounding factors. Although 17 studies were multi-centre, sample sizes varied drastically: some were extremely small with only 21 focus groups [39], while others reached 15,517 patients across 59 drug shops [34]. An epidemiological study pooled 2,301,676 tests across 317 pharmacies [49]. Three studies did not disclose funding sources [36, 41, 51] (Additional file 3).
Table 5.
Quality assessment of the included studies
| Ref no | Author | Published year | Target Disease | Randomized research design used | Availability of external control group | Multiple single centre? | Sustainability of the intervention sufficiently assessed (> 12 months) | Sample size calculation (except for qualitative studies) | Prospective data collection | Correction for confounding factors | Total no. of criteria met (out of 7) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| [23] | Ansah | 2015 | Malaria | 0 | |||||||
| [35] | Audu | 2016 | Malaria | 0 | |||||||
| [36] | Aung | 2015 | Malaria | ✓ | 1 | ||||||
| [24] | Awor | 2014 | Malaria and pneumonia | ✓ | ✓ | 2 | |||||
| [37] | Awor | 2015 | Malaria and pneumonia | ✓ | ✓ | 2 | |||||
| [38] | Cohen | 2012 | Malaria | ✓ | ✓ | 2 | |||||
| [26] | Hansen | 2017 | Malaria | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | 7 |
| [39] | Hutchinson | 2015 | Malaria | ✓ | ✓ | ✓ | ✓ | Qualitative | ✓ | 5 | |
| [40] | Hutchinson | 2017 | Malaria | ✓ | ✓ | ✓ | ✓ | Qualitative | ✓ | 5 | |
| [41] | Ikwuobe | 2013 | Malaria | ✓ | ✓ | ✓ | ✓ | ✓ | 5 | ||
| [42] | Kitutu | 2017 | Malaria, pneumonia and bloody diarrhoea | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | 6 | |
| [43] | Kwarteng | 2019 | Malaria | ✓ | ✓ | ✓ | 3 | ||||
| [44] | Maloney | 2017 | Malaria | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | 7 |
| [34] | Mboyne | 2015 | Malaria | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | 7 |
| [46] | O' Meara | 2016 | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | 6 | ||
| [47] | Poyer | 2018 | Respiratory tract infections | ✓ | ✓ | ✓ | ✓ | 4 | |||
| [49] | Simmalavong | 2017 | Malaria | ✓ | ✓ | ✓ | 3 | ||||
| [51] | Sudhinaraset | 2015 | Malaria | ✓ | ✓ | 2 | |||||
| [52] | Thet | 2021 | Malaria | ✓ | ✓ | ✓ | 3 | ||||
| [45] | Onwunduba | 2022 | Malaria | ✓ | ✓ | ✓ | 3 | ||||
| [50] | Soniran | 2022 | Malaria | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | 6 | |
| [48] | Shelus | 2023 | Malaria | ✓ | ✓ | 2 |
Moreover, differences in methods of measurement between studies hampered direct comparison – one study measured uptake as proportion of households remembering receiving POCT [36] while others only included consenting clients [23, 34]. In one study, there was significant heterogeneity in willingness to provide testing amongst 92 drug shops [38]. A standardised way of quantifying POCT uptake should be used across studies to allow for comparison – for example, recording the proportion of febrile clients or clients suspected of a particular disease by the pharmacist.
Discussion
In this review, we describe that many studies demonstrated POCT can improve diagnosis, referral, and treatment of infectious diseases [23, 24, 26, 34, 37, 44, 47]. Pharmacies are a potential point of intervention to manage infectious disease diagnosis and treatment/referral [48]. In Uganda, > 72% of care-seekers sought care for febrile children at drug shops [42, 64]. Pharmacies increase accessibility in terms of proximity to patients’ houses, cost, and opening hours compared to primary care [64]. In one study, 38% of patients presented outside normal clinic hours [62]. This may benefit populations in LMICs, whose inconsistent schedules, language barriers, or unreliable internet complicate appointment-scheduling [79]. Other studies echo the importance of pharmacies for non-emergency care-seeking [23, 80–82].
Comparison with literature
This review adds to a small body of literature on POCT in private retail settings [83]. No other review examined infectious disease testing, except Visser et al. (2016) on malaria POCTs [77]. Of the twelve papers studied, five were absent from our review: four were unpublished, while the published study compared three training intensities and sensitization and reported little effect on an overall poor uptake [84]. Although study authors reported uptake and adherence improved with longer training, frequent initial supervision, and low POCT prices, this was only based on three studies with lowest provider numbers, with multiple exceptions [77]. The authors also argued that POCT programs would not scale-up easily, but that less intense but more scalable programs had poorer outcomes [77]. This was more difficult to compare in our review considering our greater number and heterogeneity in studies. However, the authors cited similar concerns like waste management, provider and client expectations, training, and wider health-system integration [77].
Another review by Boyce et al. (2017) on malaria POCTs in sub-Saharan Africa across private, public and community healthcare included five retail studies also assessed in our review, and agreed that POCT providers had good adherence, execution, and sensitivity, but lacked specificity compared to community health workers and formal healthcare [85]. Their other concerns mirrored ours, adding that patients may purchase substandard non-ACT antimalarials, contraindicating the intent of POCTs [85]. Nevertheless, the authors’ comparison with other healthcare settings highlights the usefulness of retail settings [85].
Strengths and limitations
Our search strategy with two independent researchers means it is unlikely we missed many eligible studies within PubMed/Medline. However, five studies were neither randomised nor controlled, four were quasi-experimental (in which participants are assigned to control and intervention groups in a non-random manner), and another four were pilot studies that lacked a control arm for comparison. Moreover, under close supervision, retailers may behave differently than when unwatched – the Hawthorne Effect [34] – highlighting the usefulness of evaluation via mystery clients. Initial implementation schemes could consider a period of evaluation using this method to assess the quality of POCT performance. Moreover, data collection relying on self-reporting like household surveys/exit interviews or pharmacist questionnaires are subject to bias/recall issues. For example, Cohen et al. (2012) reported differences between POCT positivity reported by customers and providers (89% versus 60%), as customers may not admit to buying antimalarials after testing negative [38]. Recall bias may be prominent after long follow-up periods [28].
This review is limited to English studies on PubMed/Medline. High heterogeneity prevented formal meta-analysis. Most studies were on malaria, especially qualitative discussions, so outcomes are biased towards malaria studies. This review highlights the need for quality primary POCT research, particularly for non-malaria infectious diseases. For instance, there is little data on CRP, other than to differentiate viral and bacterial infections in primary healthcare [86].
Conclusion
Private retail providers are an important point-of-access for patients, facilitating prompt diagnosis and treatment. In LMICs, POCT interventions can improve treatment-seeking behaviour, reduce inappropriate antimicrobial use and resistance, and lessen the burden on public healthcare services. This review shows POCT is not only feasible in non-formal settings but also welcomed by shops and customers. Successful implementation in LMICs requires a comprehensive protocol, including community sensitization, training, reasonable pricing, infrastructure support for low-resourced pharmacies, and wider healthcare integration.
Supplementary Information
Additional file 2. Abstract screening tool.
Acknowledgements
Not applicable
Abbreviations
- POCT
Point-of-care testing
- AMR
Antimicrobial resistance
- AMS
Antimicrobial stewardship
- LMIC
Low- and middle-income countries
- CRP
C-reactive protein
- RTI
Respiratory tract infection
- mPOCT
Malaria point-of-care test
- HCV
Hepatitis C virus
Authors’ contributions
JC extracted the data, reviewed articles, and drafted and revised the paper. VN extracted the data, reviewed articles, and drafted the paper. SL supervised, reviewed and commented on the draft paper and submission. TNT, NVN, NTTD, and HRVD reviewed and commented on the draft paper.
Funding
Not applicable.
Availability of data and materials
All primary research articles are publicly available and searchable on PubMed.
Declarations
Ethics approval and consent to participate
Not applicable.
Consent for publication
Not applicable.
Competing interests
The authors declare no competing interests.
Footnotes
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
References
- 1.World Health Organization . WHO Library Cataloguing-in-Publication Data Global Action Plan on Antimicrobial Resistance. 2015. [Google Scholar]
- 2.Gerding DN. The Search for Good Antimicrobial Stewardship. Jt Comm J Qual Improv. 2001;27(8):403–404. doi: 10.1016/S1070-3241(01)27034-5. [DOI] [PubMed] [Google Scholar]
- 3.Roberts RR, Hota B, Ahmad I, et al. Hospital and societal costs of antimicrobial-resistant infections in a Chicago teaching hospital: implications for antibiotic stewardship. Clin Infect Dis. 2009;49(8):1175–1184. doi: 10.1086/605630. [DOI] [PubMed] [Google Scholar]
- 4.O’Neill J. Tackling Drug-Resistant Infections Globally: Final Report and Recommendations. 2016. [Google Scholar]
- 5.Roser M, Ritchie H. Burden of Disease. OurWorldInData.org. 2021. https://ourworldindata.org/burden-of-disease. Accessed 27 Aug 2022.
- 6.Florkowski C, Don-Wauchope A, Gimenez N, Rodriguez-Capote K, Wils J, Zemlin A. Point-of-care testing (POCT) and evidence-based laboratory medicine (EBLM) - does it leverage any advantage in clinical decision making? Crit Rev Clin Lab Sci. 54(7–8):471–494. 10.1080/10408363.2017.1399336. [DOI] [PubMed]
- 7.Huang Y, Chen R, Wu T, Wei X, Guo A. Association between point-of-care CRP testing and antibiotic prescribing in respiratory tract infections: a systematic review and meta-analysis of primary care studies. Br J Gen Pract. 2013;63(616):e787–e794. doi: 10.3399/bjgp13X674477. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8.Do NTT, Ta NTD, Tran NTH, et al. Point-of-care C-reactive protein testing to reduce inappropriate use of antibiotics for non-severe acute respiratory infections in Vietnamese primary health care: a randomised controlled trial. Lancet Glob Health. 2016;4(9):e633–e641. doi: 10.1016/S2214-109X(16)30142-5. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9.Little P, Stuart B, Francis N, et al. Effects of internet-based training on antibiotic prescribing rates for acute respiratory-tract infections: a multinational, cluster, randomised, factorial, controlled trial. Lancet. 2013;382(9899):1175–1182. doi: 10.1016/S0140-6736(13)60994-0. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 10.Cals JWL, Schot MJC, de Jong SAM, Dinant GJ, Hopstaken RM. Point-of-care C-reactive protein testing and antibiotic prescribing for respiratory tract infections: a randomized controlled trial. Ann Fam Med. 8(2):124–133. 10.1370/afm.1090. [DOI] [PMC free article] [PubMed]
- 11.Huang Y, Chen R, Wu T, Wei X, Guo A. Association between point-of-care CRP testing and antibiotic prescribing in respiratory tract infections: a systematic review and meta-analysis of primary care studies. Br J Gen Pract. 2013;63(616):e787–e794. doi: 10.3399/bjgp13X674477. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12.Larsen DA, Bennett A, Silumbe K, et al. Population-Wide Malaria Testing and Treatment with Rapid Diagnostic Tests and Artemether-Lumefantrine in Southern Zambia: A Community Randomized Step-Wedge Control Trial Design. Am J Trop Med Hyg. 2015;92(5):913–921. doi: 10.4269/ajtmh.14-0347. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13.Price CP. Point of care testing. BMJ. 2001;322(7297):1285–1288. doi: 10.1136/bmj.322.7297.1285. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 14.Jones R, Phillips I, Felix G, Tait C. An evaluation of near-patient testing for Helicobacter pylori in general practice. Aliment Pharmacol Ther. 1997;11(1):101–105. doi: 10.1046/j.1365-2036.1997.125296000.x. [DOI] [PubMed] [Google Scholar]
- 15.Heidt B, Siqueira WF, Eersels K, et al. Point of care diagnostics in resource-limited settings: a review of the present and future of PoC in its most needed environment. Biosensors (Basel). 2020;10(10). 10.3390/BIOS10100133. [DOI] [PMC free article] [PubMed]
- 16.Toskin I, Peeling RW, Mabey D, et al. Point-of-care tests for STIs: the way forward. Sex Transm Infect. 2017;93(S4). 10.1136/sextrans-2016-053074. [DOI] [PubMed]
- 17.Dinnes J, Deeks JJ, Adriano A, et al. Rapid, point-of-care antigen and molecular-based tests for diagnosis of SARS-CoV-2 infection. Cochrane Database Syst Rev. 2020;8:CD013705. doi: 10.1002/14651858.CD013705. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 18.Hansen KS, Grieve E, Mikhail A, et al. Cost-effectiveness of malaria diagnosis using rapid diagnostic tests compared to microscopy or clinical symptoms alone in Afghanistan. Malar J. 2015;14(1):217. doi: 10.1186/s12936-015-0696-1. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 19.Yadav H, Shah D, Sayed S, Horton S, Schroeder LF. Availability of essential diagnostics in ten low-income and middle-income countries: results from national health facility surveys. Lancet Glob Health. 2021;9(11):e1553–e1560. doi: 10.1016/S2214-109X(21)00442-3. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 20.Prasenjit Mitra, Praveen Sharma. POCT in developing countries. J Int Fed Clin Chem. Published online July 2021. https://www.researchgate.net/publication/353483163. [PMC free article] [PubMed]
- 21.Kunin CM, Lipton HL, Tupasi T, et al. Social, Behavioral, and Practical Factors Affecting Antibiotic Use Worldwide: Report of Task Force 4. Clin Infect Dis. 1987;9(3):S270–S285. doi: 10.1093/clinids/9.Supplement_3.S270. [DOI] [PubMed] [Google Scholar]
- 22.Yeung S, Patouillard E, Allen H, Socheat D. Socially-marketed rapid diagnostic tests and ACT in the private sector: ten years of experience in Cambodia. Malar J. 2011;10:243. doi: 10.1186/1475-2875-10-243. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 23.Ansah EK, Narh-Bana S, Affran-Bonful H, et al. The impact of providing rapid diagnostic malaria tests on fever management in the private retail sector in Ghana: a cluster randomized trial. BMJ. 2015;350:h1019. doi: 10.1136/bmj.h1019. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 24.Awor P, Wamani H, Tylleskar T, Jagoe G, Peterson S. Increased access to care and appropriateness of treatment at private sector drug shops with integrated management of malaria, pneumonia and diarrhoea: a quasi-experimental study in Uganda. PLoS One. 2014;9(12):e115440. doi: 10.1371/journal.pone.0115440. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 25.Cohen J, Fink G, Maloney K, et al. Introducing rapid diagnostic tests for malaria to drug shops in Uganda: a cluster-randomized controlled trial. Bull World Health Organ. 2015;93(3):142–151. doi: 10.2471/BLT.14.142489. [DOI] [Google Scholar]
- 26.Hansen KS, Clarke SE, Lal S, Magnussen P, Mbonye AK. Cost-effectiveness analysis of introducing malaria diagnostic testing in drug shops: A cluster-randomised trial in Uganda. PLoS One. 2017;12(12):e0189758. doi: 10.1371/journal.pone.0189758. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 27.Msellem MI, Mårtensson A, Rotllant G, et al. Influence of Rapid Malaria Diagnostic Tests on Treatment and Health Outcome in Fever Patients, Zanzibar—A Crossover Validation Study. PLoS Med. 2009;6(4):e1000070. doi: 10.1371/journal.pmed.1000070. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 28.Demoré B, Tebano G, Gravoulet J, et al. Rapid antigen test use for the management of group A streptococcal pharyngitis in community pharmacies. Eur J Clin Microbiol Infect Dis. 2018;37(9):1637–1645. doi: 10.1007/s10096-018-3293-8. [DOI] [PubMed] [Google Scholar]
- 29.Baethge C, Goldbeck-Wood S, Mertens S. SANRA—a scale for the quality assessment of narrative review articles. Res Integr Peer Rev. 2019;4(1):5. doi: 10.1186/s41073-019-0064-8. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 30.Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021:n71. 10.1136/bmj.n71. Published online March 29. [DOI] [PMC free article] [PubMed]
- 31.Polanin JR, Pigott TD, Espelage DL, Grotpeter JK. Best practice guidelines for abstract screening large-evidence systematic reviews and meta-analyses. Res Synth Methods. 2019;10(3):330–342. doi: 10.1002/jrsm.1354. [DOI] [Google Scholar]
- 32.Schweitzer VA, van Heijl I, van Werkhoven CH, et al. The quality of studies evaluating antimicrobial stewardship interventions: a systematic review. Clin Microbiol Infect. 2019;25(5):555–561. doi: 10.1016/j.cmi.2018.11.002. [DOI] [PubMed] [Google Scholar]
- 33.Mbonye AK, Clarke SE, Lal S, et al. Introducing rapid diagnostic tests for malaria into registered drug shops in Uganda: lessons learned and policy implications. Malar J. 2015;14:448. doi: 10.1186/s12936-015-0979-6. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 34.Mbonye AK, Magnussen P, Lal S, et al. A Cluster Randomised Trial Introducing Rapid Diagnostic Tests into Registered Drug Shops in Uganda: Impact on Appropriate Treatment of Malaria. PLoS One. 2015;10(7):e0129545. doi: 10.1371/journal.pone.0129545. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 35.Audu R, Anto BP, Koffuor GA, Abruquah AA, Buabeng KO. Malaria rapid diagnostic test evaluation at private retail pharmacies in Kumasi. Ghana J Res Pharm Pract. 2016;5(3):175–180. doi: 10.4103/2279-042X.185723. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 36.Aung T, White C, Montagu D, et al. Improving uptake and use of malaria rapid diagnostic tests in the context of artemisinin drug resistance containment in eastern Myanmar: an evaluation of incentive schemes among informal private healthcare providers. Malar J. 2015;14:105. doi: 10.1186/s12936-015-0621-7. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 37.Awor P, Wamani H, Tylleskar T, Peterson S. Drug seller adherence to clinical protocols with integrated management of malaria, pneumonia and diarrhoea at drug shops in Uganda. Malar J. 2015;14:277. doi: 10.1186/s12936-015-0798-9. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 38.Cohen J, Fink G, Berg K, et al. Feasibility of distributing rapid diagnostic tests for malaria in the retail sector: evidence from an implementation study in Uganda. PLoS One. 2012;7(11):e48296. doi: 10.1371/journal.pone.0048296. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 39.Hutchinson E, Chandler C, Clarke S, et al. “It puts life in us and we feel big”: shifts in the local health care system during the introduction of rapid diagnostic tests for malaria into drug shops in Uganda. Crit Public Health. 2015;25(1):48–62. doi: 10.1080/09581596.2014.886762. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 40.Hutchinson E, Hutchison C, Lal S, et al. Introducing rapid tests for malaria into the retail sector: what are the unintended consequences? BMJ Glob Health. 2017;2(1):e000067. doi: 10.1136/bmjgh-2016-000067. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 41.Ikwuobe JO, Faragher BE, Alawode G, Lalloo DG. The impact of rapid malaria diagnostic tests upon anti-malarial sales in community pharmacies in Gwagwalada. Nigeria Malar J. 2013;12:380. doi: 10.1186/1475-2875-12-380. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 42.Kitutu FE, Kalyango JN, Mayora C, Selling KE, Peterson S, Wamani H. Integrated community case management by drug sellers influences appropriate treatment of paediatric febrile illness in South Western Uganda: a quasi-experimental study. Malar J. 2017;16(1):425. doi: 10.1186/s12936-017-2072-9. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 43.Kwarteng A, Malm KL, Febir LG, et al. The Accuracy and Perception of Test-Based Management of Malaria at Private Licensed Chemical Shops in the Middle Belt of Ghana. Am J Trop Med Hyg. 2019;100(2):264–274. doi: 10.4269/ajtmh.17-0970. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 44.Maloney K, Ward A, Krenz B, et al. Expanding access to parasite-based malaria diagnosis through retail drug shops in Tanzania: evidence from a randomized trial and implications for treatment. Malar J. 2017;16(1):6. doi: 10.1186/s12936-016-1658-y. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 45.Onwunduba A, Ekwunife O, Onyilogwu E. Impact of point-of-care C-reactive protein testing intervention on non-prescription dispensing of antibiotics for respiratory tract infections in private community pharmacies in Nigeria: a cluster randomized controlled trial. Int J Infect Dis. 2023;127:137–143. doi: 10.1016/j.ijid.2022.12.006. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 46.Prudhomme O’Meara W, Mohanan M, Laktabai J, et al. Assessing the independent and combined effects of subsidies for antimalarials and rapid diagnostic testing on fever management decisions in the retail sector: results from a factorial randomised trial in western Kenya. BMJ Glob Health. 2016;1(2):e000101. doi: 10.1136/bmjgh-2016-000101. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 47.Poyer S, Musuva A, Njoki N, et al. Fever case management at private health facilities and private pharmacies on the Kenyan coast: analysis of data from two rounds of client exit interviews and mystery client visits. Malar J. 2018;17(1):112. doi: 10.1186/s12936-018-2267-8. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 48.Herbin SR, Klepser DG, Klepser ME. Pharmacy-based infectious disease management programs incorporating CLIA-waived point-of-care tests. J Clin Microbiol. 2020;58(5). 10.1128/JCM.00726-19. [DOI] [PMC free article] [PubMed]
- 49.Simmalavong N, Phommixay S, Kongmanivong P, et al. Expanding malaria diagnosis and treatment in Lao PDR: lessons learned from a public-private mix initiative. Malar J. 2017;16(1):460. doi: 10.1186/s12936-017-2104-5. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 50.Soniran OT, Mensah BA, Cheng NI, Abuaku B, Ahorlu CS. Improved adherence to test, treat, and track (T3) malaria strategy among Over-the-Counter Medicine Sellers (OTCMS) through interventions implemented in selected rural communities of Fanteakwa North district, Ghana. Malar J. 2022;21(1):317. doi: 10.1186/s12936-022-04338-9. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 51.Sudhinaraset M, Briegleb C, Aung M, Khin HS, Aung T. Motivation and challenges for use of malaria rapid diagnostic tests among informal providers in Myanmar: a qualitative study. Malar J. 2015;14:61. doi: 10.1186/s12936-015-0585-7. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 52.Thet MM, Khaing MNT, Zin SS, Oo S, Aung YK, Thein ST. Role of small private drug shops in malaria and tuberculosis programs in Myanmar: a cross-sectional study. J Pharm Policy Pract. 2021;14(Suppl 1):89. doi: 10.1186/s40545-021-00335-6. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 53.Shelus V, Mumbere N, Mulogo EM, et al. Private sector antimalarial sales a decade after “test and treat”: a cross-sectional study of drug shop clients in rural Uganda. Front Public Health. 2023;11. 10.3389/fpubh.2023.1140405. [DOI] [PMC free article] [PubMed]
- 54.Pai NP, Wilkinson S, Deli-Houssein R, et al. Barriers to Implementation of Rapid and Point-of-Care Tests for Human Immunodeficiency Virus Infection. Point of Care: The Journal of Near-Patient Testing & Technology. 2015;14(3):81–87. doi: 10.1097/POC.0000000000000056. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 55.Harvey SA, Jennings L, Chinyama M, Masaninga F, Mulholland K, Bell DR. Improving community health worker use of malaria rapid diagnostic tests in Zambia: package instructions, job aid and job aid-plus-training. Malar J. 2008;7(1):160. doi: 10.1186/1475-2875-7-160. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 56.Cristillo AD, Bristow CC, Peeling RR, et al. Point-of-Care Sexually Transmitted Infection Diagnostics: Proceedings of the STAR Sexually Transmitted Infection—Clinical Trial Group Programmatic Meeting. Sex Transm Dis. 2017;444(4):211–18. doi: 10.1097/OLQ.0000000000000572. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 57.Rusk A, Goodman C, Naanyu V, Koech B, Obala A, O’Meara WP. Expanding Access to Malaria Diagnosis through Retail Shops in Western Kenya: What Do Shop Workers Think? Malar Res Treat. 2013;2013:1–9. doi: 10.1155/2013/398143. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 58.Kugelmas M, Pedicone LD, Lio I, Simon S, Pietrandoni G. Hepatitis C Point-of-Care Screening in Retail Pharmacies in the United States. Gastroenterol Hepatol (N Y) 2017;13(2):98–104. [PMC free article] [PubMed] [Google Scholar]
- 59.Shelus V, Mumbere N, Masereka A, et al. “Testing for malaria does not cure any pain” A qualitative study exploring low use of malaria rapid diagnostic tests at drug shops in rural Uganda. PLOS Global Public Health. 2022;2(12):e0001235. doi: 10.1371/journal.pgph.0001235. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 60.Klepser ME, Klepser DG, Dering-Anderson AM, Morse JA, Smith JK, Klepser SA. Effectiveness of a pharmacist-physician collaborative program to manage influenza-like illness. J Am Pharm Assoc (2003) 2016;56(1):14–21. doi: 10.1016/j.japh.2015.11.008. [DOI] [PubMed] [Google Scholar]
- 61.Klepser DG, Klepser ME, Murry JS, Borden H, Olsen KM. Evaluation of a community pharmacy-based influenza and group A streptococcal pharyngitis disease management program using polymerase chain reaction point-of-care testing. J Am Pharm Assoc (2003) 2019;59(6):872–879. doi: 10.1016/j.japh.2019.07.011. [DOI] [PubMed] [Google Scholar]
- 62.Klepser DG, Klepser ME, Smith JK, Dering-Anderson AM, Nelson M, Pohren LE. Utilization of influenza and streptococcal pharyngitis point-of-care testing in the community pharmacy practice setting. Res Social Adm Pharm. 2018;14(4):356–359. doi: 10.1016/j.sapharm.2017.04.012. [DOI] [PubMed] [Google Scholar]
- 63.Hardin R, Roberts P, Hudspeth B, et al. Development and implementation of an influenza point-of-care testing service in a chain community pharmacy setting. Pharmacy (Basel). 2020;8(4). 10.3390/pharmacy8040182. [DOI] [PMC free article] [PubMed]
- 64.Hohmeier KC, McKeirnan K, Akers J, et al. Implementing community pharmacy-based influenza point-of-care test-and-treat under collaborative practice agreement. Implement Sci Commun. 2022;3(1):77. doi: 10.1186/s43058-022-00324-z. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 65.Kherghehpoush S, McKeirnan KC. Pharmacist-led HIV and hepatitis C point-of-care testing and risk mitigation counseling in individuals experiencing homelessness. Explor Res Clin Soc Pharm. 2021;1:100007. doi: 10.1016/j.rcsop.2021.100007. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 66.O’Connor SK, Healey P, Mark N, Adams JL, Robinson R, Nguyen E. Developing sustainable workflows for community pharmacy-based SARS-CoV-2 testing. J Am Pharm Assoc (2003) 2022;62(1):253–259. doi: 10.1016/j.japh.2021.08.012. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 67.Czarniak P, Chalmers L, Hughes J, et al. Point-of-care C-reactive protein testing service for respiratory tract infections in community pharmacy: a qualitative study of service uptake and experience of pharmacists. Int J Clin Pharm. 2022;44(2):466–479. doi: 10.1007/s11096-021-01368-2. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 68.Bastiaens GJH, Bousema T, Leslie T. Scale-up of Malaria Rapid Diagnostic Tests and Artemisinin-Based Combination Therapy: Challenges and Perspectives in Sub-Saharan Africa. PLoS Med. 2014;11(1):e1001590. doi: 10.1371/journal.pmed.1001590. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 69.Chandler CIR, Hall-Clifford R, Asaph T, Pascal M, Clarke S, Mbonye AK. Introducing malaria rapid diagnostic tests at registered drug shops in Uganda: Limitations of diagnostic testing in the reality of diagnosis. Soc Sci Med. 2011;72(6):937–944. doi: 10.1016/j.socscimed.2011.01.009. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 70.Isiguzo C, Anyanti J, Ujuju C, et al. Presumptive Treatment of Malaria from Formal and Informal Drug Vendors in Nigeria. PLoS One. 2014;9(10):e110361. doi: 10.1371/journal.pone.0110361. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 71.Mangham LJ, Cundill B, Ezeoke O, et al. Treatment of uncomplicated malaria at public health facilities and medicine retailers in south-eastern Nigeria. Malar J. 2011;10(1):155. doi: 10.1186/1475-2875-10-155. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 72.Kawachi A, Sakamoto Y, Mouri S, et al. The detection of influenza virus at the community pharmacy to improve the management of local residents with influenza or influenza-like disease. J Pharm Health Care Sci. 2017;3:22. doi: 10.1186/s40780-017-0091-x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 73.Kirby J, Mousa N. Evaluating the impact of influenza and streptococcus point-of-care testing and collaborative practice prescribing in a community pharmacy setting. J Am Pharm Assoc (2003) 2020;60(3S):S70–S75. doi: 10.1016/j.japh.2020.03.003. [DOI] [PubMed] [Google Scholar]
- 74.Papastergiou J, Trieu CR, Saltmarche D, Diamantouros A. Community pharmacist-directed point-of-care group A Streptococcus testing: Evaluation of a Canadian program. J Am Pharm Assoc (2003) 2018;58(4):450–456. doi: 10.1016/j.japh.2018.03.003. [DOI] [PubMed] [Google Scholar]
- 75.Thornley T, Marshall G, Howard P, Wilson AP. A feasibility service evaluation of screening and treatment of group A streptococcal pharyngitis in community pharmacies. J Antimicrob Chemother. 2016;71(11):3293–3299. doi: 10.1093/jac/dkw264. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 76.Burchett HED, Leurent B, Baiden F, et al. Improving prescribing practices with rapid diagnostic tests (RDTs): synthesis of 10 studies to explore reasons for variation in malaria RDT uptake and adherence. BMJ Open. 2017;7(3):e012973. doi: 10.1136/bmjopen-2016-012973. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 77.Visser T, Bruxvoort K, Maloney K, et al. Introducing malaria rapid diagnostic tests in private medicine retail outlets: A systematic literature review. PLoS One. 2017;12(3):e0173093. doi: 10.1371/journal.pone.0173093. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 78.Chen IT, Aung T, Thant HNN, Sudhinaraset M, Kahn JG. Cost-effectiveness analysis of malaria rapid diagnostic test incentive schemes for informal private healthcare providers in Myanmar. Malar J. 2015;14(1):55. doi: 10.1186/s12936-015-0569-7. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 79.Patel J, Christofferson N, Goodlet KJ. Pharmacist-provided SARS-CoV-2 testing targeting a majority-Hispanic community during the early COVID-19 pandemic: Results of a patient perception survey. J Am Pharm Assoc. 2022;62(1):187–193. doi: 10.1016/j.japh.2021.08.015. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 80.World Health Organization . Guidelines for the Treatment of Malaria. 2. 2010. [PubMed] [Google Scholar]
- 81.Nankabirwa J, Zurovac D, Njogu JN, et al. Malaria misdiagnosis in Uganda – implications for policy change. Malar J. 2009;8(1):66. doi: 10.1186/1475-2875-8-66. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 82.O’Connell KA, Gatakaa H, Poyer S, et al. Got ACTs? Availability, price, market share and provider knowledge of anti-malarial medicines in public and private sector outlets in six malaria-endemic countries. Malar J. 2011;10(1):326. doi: 10.1186/1475-2875-10-326. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 83.Lam TT, Dang DA, Tran HH, et al. What are the most effective community-based antimicrobial stewardship interventions in low- and middle-income countries? A narrative review. J Antimicrob Chemother. 2021;76(5):1117–1129. doi: 10.1093/jac/dkaa556. [DOI] [PubMed] [Google Scholar]
- 84.Onwujekwe O, Uguru N, Russo G, et al. Role and use of evidence in policymaking: an analysis of case studies from the health sector in Nigeria. Health Res Policy Syst. 2015;13(1):46. doi: 10.1186/s12961-015-0049-0. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 85.Boyce MR, O’Meara WP. Use of malaria RDTs in various health contexts across sub-Saharan Africa: a systematic review. BMC Public Health. 2017;17(1):470. doi: 10.1186/s12889-017-4398-1. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 86.Huddy JR, Ni MZ, Barlow J, Majeed A, Hanna GB. Point-of-care C reactive protein for the diagnosis of lower respiratory tract infection in NHS primary care: a qualitative study of barriers and facilitators to adoption. BMJ Open. 2016;6(3):e009959. doi: 10.1136/bmjopen-2015-009959. [DOI] [PMC free article] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Supplementary Materials
Additional file 2. Abstract screening tool.
Data Availability Statement
All primary research articles are publicly available and searchable on PubMed.

